Table II.
Effect of levodopa/carbidopa intestinal gel on OFF time
| Authors (ref.) | Study design | N. of patients | Duration | Reduction in OFF time vs baseline |
|---|---|---|---|---|
| Nyholm et al., 2005 (33) | Randomized, controlled vs oral levodopa | 24 | 3+3 weeks | Significant reduction in OFF time (p<0.01) |
| Stocchi et al., 2005 (30) | Open | 6 | 6 months | −78% in daily hours in OFF (p<0.001) |
| Eggert et al., 2008 (35) | Open | 13 | 12 months | −70% in daily hours in OFF |
| Antonini et al., 2007 (36) | Open, prospective | 9 | 12 months | −89% in mean OFF time vs baseline (p<0.01) |
| Antonini et al., 2008 (40) | Open, prospective | 22 | 24 months | −46% in mean OFF time (UPDRS IV) (p<0.05) |
| Santos-Garcia et al., 2011 (48) | Open, prospective | 5 | 6 months | −91% in OFF time (p<0.05) |
| Puente et al., 2010 (38) | Open, prospective | 9 | 18 months | Reduction in UPDRS III score, OFF from 39.7 to 29.4; (p<0.05) |
| Merola et al., 2011 (39) | Open, retrospective vs deep brain stimulation | 20 | 15 months | Significant reduction (p<0.05) in time during waking day spent in OFF (item 39) |